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Abstract
The first total synthesis of (+)-luteoalbusins A and B is described. Highly regio- and 
diastereoselective chemical transformations in our syntheses include a Friedel-Crafts C3-indole 
addition to a cyclotryptophan derived diketopiperazine, a late-stage diketopiperazine 
dihydroxylation and C11-sulfidation sequence, in addition to congener-specific polysulfane 
synthesis and cyclization to the corresponding epipolythiodiketopiperazine. We also report the 
cytoxicity of both alkaloids, and closely related derivatives, against A549, HeLa, HCT116 and 
MCF7 human cancer cell lines.
Graphical abstract
Epipolythiodiketopiperazine alkaloids represent a structurally complex and biologically 
active class of secondary fungal metabolites.1,2 Many members of this family of natural 
products share a cyclo-tryptophan core and an eponymous epipolythiodiketopiperazine 
(ETP) substructure (Figure 1). Notwithstanding these similarities, individual ETP alkaloids 
offer an array of structural variations including the nature of the substituent at the C3 
quaternary carbon,3,4,5 the degree of oxidation of the core structure,4l,n the dipeptide 
constituting the diketopiperazine substructure, in addition to the nature and degree of 
sulfuration of the ETP structure.3n,4i,6 Access to complex ETPs via total synthesis requires 
efficient strategies and chemical transformations adaptable to this repertoire of structural 
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diversity along with the respective challenges offered by each distinct combination. As part 
of our program focused on accessing structurally unique ETP alkaloids, we became 
interested in (+)-luteoalbusin A (1) and (+)-luteoalbusin B (2), recently discovered ETPs 
isolated from the marine fungi, Acrostalagmus luteoalbus SCSIO F457, by Wang and 
coworkers.7 These natural products contain a C3-(3'-indolyl) substituent and an ETP 
substructure, possessing a di or tri-sulfide bridge with a diketopiperazine composed of 
tryptophan and serine. These structural features of (+)-luteoalbusins A (1) and B (2) are 
shared in part with the related ETP alkaloids (+)-gliocladin B and (+)-chaetocins A and C 
(Figure 1) that were the subject of our prior investigations.3n,4i Herein, we report the first 
total syntheses of (+)- luteoalbusins A (1) and B (2) using a concise and unified approach as 
well as their cytotoxic activity against four human cancer cell lines.
Our retrosynthetic analysis of these natural alkaloids is illustrated in Scheme 1. We 
envisioned having efficient access to both alkaloids from a versatile C11-thiolated 
diketopiperazine 3 via the application of our polysulfane cyclization chemistry to accurately 
introduce the disulfane and trisulfane substructures in the final stage of the synthesis.3n,6o 
The regio- and diastereoselective C11-sulfidation of the key dihydroxylated 
diketopiperazine (+)-4 was planned based on the faster expected rate of iminium ion 
formation at C11 vs. C15 due to the inductive electron withdrawing influence of the C17 
acetate. Rapid access to the key intermediate (+)-4 was expected through introduction of the 
C3-indolyl substituent by Friedel-Crafts arylation4d followed by application of our 
diketopiperazine dihydroxylation chemistry.3l Tetracyclic diketopiperazine bromide (+)-5 is 
readily available in multigram scale as outlined in our synthesis of (+)-chaetocins A and 
C.3n
Our unified synthesis of alkaloids (+)-1 and (+)-2 began with the silver-mediated Friedel-
Crafts arylation of diketopiperazine (+)-5 (Scheme 2).8 Based on our earlier studies 
concerning the regioselective introduction of the C3-indolyl substructure, we employed the 
readily available 1-(triisopropylsilyl)-1H-indole (6) to provide the C3–C3' linkage, 
exclusively.4i Treatment of a solution of C3-bromo diketopiperazine (+)-5 in 
dichloromethane with indole derivative 6 and silver(I) hexafluoroantimonate in the presence 
of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) at 23 °C afforded the desired C3-
indolylhexacycle (+)-7 in 77% yield. Exposure of C3-bromoindolyl diketopiperazine and 
palladium on carbon to an atmosphere of dihydrogen in ethyl acetate–methanol (2:3) at 23 
°C gave C3-indolyl diketopiperazine (+)-8 in 80% yield. Consistent with our biogenetically 
inspired strategy for synthesis of ETP alkaloids,2f,3l further functionalization of the 
diketopiperazine substructure was addressed after construction of the hexacyclic core. 
Treatment of diketopiperazine (+)-8 in acetonitrile with bis(pyridine)silver(I) permanganate 
(Py2AgMnO4) provided the desired dihydroxylated diketopiperazine (+)-4 as a single 
diastereomer in 66% yield.3l,9 This oxidation reaction likely proceeds via a stereoretentive 
radical rebound mechanism with initial hydrogen atom abstraction, followed by trapping of 
the generated carbon centered radical.10 For the subsequent sulfidation of the C11 position, 
we have previously observed in related systems that non-nucleophilic solvents are necessary 
for the selective ionization of the C11 alcohol and trapping with an alkyl mercaptan.4n 
Furthermore, due to the inductive effect of the neighboring heteroatom at C17, the rate of 
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ionization at the C15 position was anticipated to be decreased.3n Thus, exposure of diol 
(+)-4 to trifluoroacetic acid (TFA) in hydrogen sulfide saturated nitroethane at 0 °C 
produced monothiol 9 with concomitant loss of the tri-iso-propylsilyl group at the N1' 
position. After concentrating the reaction mixture, the residue was treated with 4-
dimethylaminopyridine (DMAP) and isobutyryl chloride in dichloromethane at 0 °C to 
generate the desired isobutyrylthioester (+)-10 in 83% yield over two steps. The isobutyrate 
groups at C11 and C15 served two purposes: Firstly, activation of the tertiary alcohol at C15 
through esterification with isobutyryl chloride is required for the polysulfane cyclization 
step. Secondly, acylation of the C11 thiol was necessary to enhance the stability of the 
molecule for the photoinduced removal of the N1-benzenesulfonyl group.11 Thus, 
irradiation of benzenesulfonyl (+)-10 with light (350 nm) in the presence of 1,4-
dimethoxynapthalene (1,4-DMN) in buffered aqueous ascorbic acid–acetonitrile solution 
afforded the desired key indoline (+)-11 in 69% yield.
The final stages of our synthesis of (+)-luteoalbusin A (1) relied on selective hydrazinolysis 
of the thioisobutyryl group at C11 over the C15 isobutyrate by treatment with one equivalent 
of hydrazine in THF at 0 °C (Scheme 3). Subsequent exposure of the hemithioaminal 3 to 
triphenylmethanesulfenyl chloride (TrSCl) and triethylamine provided the desired mixed 
disulfide (−)-12 in 98% yield.3n Activation of the C15 isobutyrate group and subsequent 
cyclization of the disulfide with concomitant loss of the triphenylmethyl cation was 
accomplished through the treatment of disulfide (−)-12 with boron trifluoride diethyl 
etherate in dichloromethane at 23 °C to furnish (+)-luteoalbusin A acetate (13) in 95% yield. 
Unveiling of the C17 alcohol from acetate (+)-13 was achieved by utilizing trimethyltin 
hydroxide12 in toluene at 90 °C to afford (+)-luteoalbusin A (1) in 73% yield. All 
spectroscopic data for our synthetic sample of (+)-luteoalbusin A (1) are consistent with 
those reported by the Wang.7,8
The total synthesis of (+)-luteoalbusin B (2) also utilized the key intermediate 
thioisobutyrate (+)-11. Sequential treatment of thioisobutyrate (+)-11 with hydrazine, 
followed by the addition of chloro(triphenylmethyl)disulfane (TrSSCl)8 under basic 
conditions as described above produced the corresponding mixed trisulfide (+)-14 in 85% 
yield (Scheme 3).3n Notably, exposure of trisulfide (+)-14 to boron trifluoride diethyl 
etherate in dichloromethane resulted in decomposition of the substrate, an outcome likely 
caused by competing pathways involving the indoline nitrogen due to a decrease in the rate 
of cyclization relative to disulfide (−)-12.3n Based on this observation we reasoned that 
protection of the N1 indoline nitrogen of trisulfide (+)-14 as well as employing a solvent 
with higher dielectric constant might increase the cyclization efficiency. Thus, in situ 
acylation of the N1 indoline nitrogen of trisulfide (+)-14 with trifluoroacetic anhydride and 
DTBMP in acetonitrile, followed by the addition of boron trifluoride diethyletherate at 23 
°C afforded the desired epitrithiodiketopiperazine (+)-15 in 43% yield.
Importantly, replacing boron trifluoride diethyletherate with hafnium 
trifluoromethanesulfonate as the Lewis acid additive further enhanced the cyclization of the 
trisulfide to provide epitrithiodiketopiperazine (+)-15 in 92% yield as a 1.6:1 mixture of 
epitrisulfide conformers (Scheme 3). Sequential C17-deacylation of luteoalbusin B 
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derivative (+)-15 by mild methanolysis using Otera’s catalyst13 followed by N1-deacylation 
by hydrazinolysis3n afforded the first synthetic sample of (+)-luteoalbusin B (2) in 71% 
yield as a 4:1 mixture of epitrisulfide conformers. All spectroscopic data for our synthetic 
sample of (+)-luteoalbusin B (2) are consistent with those reported by the Wang.7,8
Epipolythiodiketopiperazine alkaloids are known to possess an impressive array of potent 
biological activities including anticancer,6o,q antiviral, and antibacterial properties.14 Earlier 
studies have linked the unique biological activity of these natural products to their 
polysulfide structures.14h,i Recently, we disclosed a comprehensive SAR study of a large 
collection of natural and synthetic ETP derivatives for cytotoxic activity against multiple 
human cancer cell lines.6o As part of our ongoing interest to evaluate the translational 
potential of ETPs, we examined synthetic (+)-luteoalbusins A (1) and B (2) as well as all 
novel synthetic intermediates described above prepared en route to both natural products for 
cytotoxic activity against human lung carcinoma (A549), cervical carcinoma (HeLa), 
colorectal carcinoma (HCT116) and breast carcinoma (MCF7) cell lines.8 Among all 
compounds tested, natural products (+)-1 and (+)-2 and acetylated derivatives (+)-13 and 
(+)-15, also possessing a bridged polysulfide, were found to exhibit significant anti-cancer 
activity (Table 1). Both natural alkaloids (+)-1 and (+)-2 displayed consistently high 
cytotoxicity across all cell lines tested. However, the C17 acetylated deriviatives ETP (+)-13 
and ETP (+)-15 were found to be less potent relative to the (+)-luteoalbusins A (1) and B 
(2), respectively. The IC50 values for ETPs (+)-1, (+)-2, (+)-13, and (+)-15 across the four 
human cancer cell lines tested are listed in Table 1. Our results complement those reported 
by the Wang group.15
We report the first total synthesis of (+)-luteoalbusins A (1) and B (2). This unified synthetic 
strategy was based on our versatile and biogenetically inspired2f late-stage functionalization 
of a complex diketopiperazine via an oxidation followed by sulfidation sequence to access 
the desired epidi- and epitrithiodiketopiperazines 1 and 2, respectively. Our synthesis relied 
on highly regioand diastereoselective chemical transformations including a Friedel-Crafts 
C3-indole addition to the readily available diketopiperazine (+)-5, dihydroxylation and C11-
sulfidation of C3-(3'-indoyl)diketopiperazine (+)-8, and the use of a versatile thioisobutyrate 
(+)-11 as a substrate for congener-specific polysulfane synthesis and cyclization to access 
both (+)-luteoalbusins A (1) and B (2). We also report the cytoxicity of both alkaloids (+)-1 
and 2 along with closely related ETPs (+)-13 and (+)-15 against A549, HeLa, HCT116 and 
MCF7 human cancer cell lines.
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Preparation of Key Intermediate (+)-11
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Synthesis of (+)-Luteoalbusin A (1) and B (2)
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Table 1
Cytotoxicity (IC50, µM) of (+)-Luteoalbusin A and B and related derivatives against A549, HeLa, HCT116 
and MCF7 cancer cell lines8
Compd A549 HeLa HCT116 MCF7
(+)-13 11.31 ± 2.54 5.50 ± 2.81 4.73 ± 4.34 5.17 ± 0.20
(+)-15 11.02 ± 0.23 5.19 ± 2.05 5.11 ± 3.37 6.53 ± 0.84
(+)-1 2.33 ± 0.59 1.00 ± 0.24 1.22 ± 1.02 0.86 ± 0.13
(+)-2 0.91 ± 0.29 0.52 ± 0.15 0.58 ± 0.38 0.51 ± 0.14
Org Lett. Author manuscript; available in PMC 2016 September 04.
